Search Results - "Kosiborod, MN"

Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management by Vora, Jiten, Cherney, David, Kosiborod, Mikhail N., Spaak, Jonas, Kanumilli, Naresh, Khunti, Kamlesh, Lam, Carolyn S. P., Bachmann, Michael, Fenici, Peter

“…Cardiovascular, renal and metabolic (CaReMe) diseases are individually among the leading global causes of death, and each is associated with substantial…”
Get full text

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial by Butler, Javed, Anker, Stefan D., Siddiqi, Tariq Jamal, Coats, Andrew J. S., Dorigotti, Fabio, Filippatos, Gerasimos, Friede, Tim, Göhring, Udo‐Michael, Kosiborod, Mikhail N., Lund, Lars H., Metra, Marco, Moreno Quinn, Carol, Piña, Ileana L., Pinto, Fausto J., Rossignol, Patrick, Szecsödy, Peter, Van Der Meer, Peter, Weir, Matthew, Pitt, Bertram

“…© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access…”
Get full text

Aldosterone and aldosterone synthase inhibitors in cardiorenal disease by Verma, Subodh, Pandey, Avinash, Pandey, Arjun K, Butler, Javed, Lee, John S, Teoh, Hwee, Mazer, C David, Kosiborod, Mikhail N, Cosentino, Francesco, Anker, Stefan D, Connelly, Kim A, Bhatt, Deepak L

“…Modulation of the renin-angiotensin-aldosterone system is a foundation of therapy for cardiovascular and kidney diseases. Excess aldosterone plays an important…”
Get more information

Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF by Bhatt, Ankeet S, Bhatt, Deepak L, Steg, Ph Gabriel, Szarek, Michael, Cannon, Christopher P, Leiter, Lawrence A, McGuire, Darren K, Lewis, Julia B, Riddle, Matthew C, Voors, Adriaan A, Metra, Marco, Lund, Lars H, Testani, Jeffrey M, Wilcox, Christopher S, Davies, Michael, Pitt, Bertram, Kosiborod, Mikhail N

“…Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve health status in heart failure (HF) across the left ejection fraction ejection spectrum. However, the…”
Get full text

Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease by Rossignol, P., Silva-Cardoso, J., Kosiborod, MN, Brandenburg, V., Cleland, JG, Hadimeri, H., Hullin, R., Makela, S., Mörtl, D., Paoletti, E., Pollock, C., Vogt, L., Jadoul, M., Butler, J.

“…Pivotal randomized trials demonstrating efficacy, safety and good tolerance, of two new potassium binders (patiromer and sodium zirconium cyclosilicate) led to…”
Get full text

Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia by Pitt, Bertram, Anker, Stefan D., Lund, Lars H., Coats, Andrew J.S., Filippatos, Gerasimos, Rossignol, Patrick, Weir, Matthew R., Friede, Tim, Kosiborod, Mikhail N., Metra, Marco, Böhm, Michael, Ezekowitz, Justin A., Bayes-Genis, Antoni, Mentz, Robert J., Ponikowski, Piotr, Senni, Michele, Piña, Ileana L., Pinto, Fausto J., van der Meer, Peter, Bahit, Cecilia, Belohlavek, Jan, Brugts, Jasper J., Perrin, Amandine, Waechter, Sandra, Budden, Jeffrey, Butler, Javed

“…Hyperkalemia (HK) is associated with suboptimal renin–angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure…”
Get full text

Lower risk of cardiovascular events and death associated with initiation of sodium‐glucose cotransporter‐2 inhibitors versus sulphonylureas: Analysis from the CVD‐REAL 2 study by Goh, Su‐Yen, Kosiborod, Mikhail N., Lam, Carolyn S. P., Cavender, Matthew A., Kohsaka, Shun, Norhammar, Anna, Birkeland, Kåre I., Holl, Reinhard W., Mauricio, Dídac, Tangri, Navdeep, Shaw, Jonathan E., Thuresson, Marcus, Fenici, Peter, Kim, Dae Jung

Get full text

Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF by Pitt, Bertram, Bhatt, Deepak L, Szarek, Michael, Cannon, Christopher P, Leiter, Lawrence A, McGuire, Darren K, Lewis, Julia B, Riddle, Matthew C, Voors, Adriaan A, Metra, Marco, Lund, Lars H, Komajda, Michel, Testani, Jeffrey M, Wilcox, Christopher S, Ponikowski, Piotr, Lopes, Renato D, Ezekowitz, Justin A, Sun, Franklin, Davies, Michael J, Verma, Subodh, Kosiborod, Mikhail N, Steg, Ph Gabriel

“…Approximately 25% of patients admitted to hospitals for worsening heart failure (WHF) are readmitted within 30 days. The authors conducted a post hoc analysis…”
Get full text

Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort by Fishbane, Steven, Carrero, Juan-Jesus, Kumar, Supriya, Kanda, Eiichiro, Hedman, Katarina, Ofori-Asenso, Richard, Kashihara, Naoki, Kosiborod, Mikhail N, Lainscak, Mitja, Pollock, Carol, Stenvinkel, Peter, Wheeler, David C, Pecoits-Filho, Roberto

“…Key Points Hyperkalemia (HK) is associated with increased comorbidity burden in patients with CKD. Reducing serum potassium levels after HK episodes helps…”
Get full text

Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility by James, Glen, Garcia Sanchez, Juan Jose, Carrero, Juan Jesus, Kumar, Supriya, Pecoits-Filho, Roberto, Heerspink, Hiddo J.L., Nolan, Stephen, Lam, Carolyn S.P., Chen, Hungta, Kanda, Eiichiro, Kashihara, Naoki, Arnold, Matthew, Kosiborod, Mikhail N., Lainscak, Mitja, Pollock, Carol, Wheeler, David C.

“…Kidney Disease: Improving Global Outcomes (KDIGO) 2012 guidelines classify chronic kidney disease (CKD) risk or prognosis using estimated glomerular filtration…”
Get full text

Correction by Pitt, B, Bhatt, DL, Szarek, M, Cannon, CP, Leiter, LA, Mcguire, DK, Lewis, JB, Riddle, MC, Voors, AA, Metra, M, Lund, LH, Komajda, M, Testani, JM, Wilcox, CS, Ponikowski, P, Lopes, RD, Ezekowitz, JA, Sun, F, Davies, MJ, Verma, S, Kosiborod, MN, Steg, PG

Get full text